One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Discover OPKO Health's Q2 2025 earnings insights, highlighting asset sales, cost savings, and pipeline advancements.

June was a slower month on the pharma agency side, but were several hires worth reporting, as well as a couple of interesting ...

By the end of 2024, Axmed had partnered with over 20 organizations across 15 countries. It processed more than 4,200 orders, ...

Signals suggest the drugs could improve on the standard of care, but the market may not make it easy for another megablockbuster to rise to the top.

It might be prudent to make a point of collecting a little more cash in the near future, and worry a little less about growth ...

On July 30, 2025, Pfizer (PFE) saw its shares drop by 2.02%, with a trading volume hitting $0.86 billion and ranking 118th in ...

New capital, maturing pipelines, and a more global R&D mindset are pushing valuations higher, even as competition tightens.

With Virgin shares holding nicely at cruising altitude, is now the right time for private oncology drug developer Qbiotics to ...

On July 25, Leads Biolabs made its official debut on the Hong Kong Stock Exchange. Its shares surged as much as 117% intraday ...